Anti-PI 3 Kinase p85 alpha (phospho Y607) antibody (ab182651)
Key features and details
- Rabbit polyclonal to PI 3 Kinase p85 alpha (phospho Y607)
- Suitable for: IHC-P, WB
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-PI 3 Kinase p85 alpha (phospho Y607) antibody
See all PI 3 Kinase p85 alpha primary antibodies -
Description
Rabbit polyclonal to PI 3 Kinase p85 alpha (phospho Y607) -
Host species
Rabbit -
Specificity
ab182651 detects endogenous level of PI 3 Kinase p85 only when phosphorylated at Tyrosine 607.
-
Tested applications
Suitable for: IHC-P, WBmore details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide corresponding to Human PI 3 Kinase p85 alpha (phospho Y607) conjugated to keyhole limpet haemocyanin. Peptide sequence around phosphorylation site of Tyrosine 607 (D-Q-Y(p)-S-L) derived from Human PI3K p85.
Database link: P27986 -
Positive control
- WB: Insulin treated HeLa cell lysates. HeLa cells. Rat liver extract. MCF-7 cell lysate; mouse brain tissue lysate; rat brain tissue lysate. IHC-P: Human brain tissue.
-
General notes
This product may cross-react with family member PIK3R2 due to the high homology with this protein around the phosphosite.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 49% PBS, 50% Glycerol, 0.88% Sodium chloride
Without Mg2+ and Ca2+ -
Concentration information loading... -
Purity
Immunogen affinity purified -
Purification notes
ab182651 was purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab182651 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| IHC-P |
Use at an assay dependent concentration.
|
|
| WB | (1) |
1/500 - 1/1000. Predicted molecular weight: 84 kDa.
Block membrane by incubating 1 hour at room temperature or overnight at 4 °C with shaking in Blocking Solution(5% BSA, 1X TBS, 0.1% Tween-20). Incubate the membrane with diluted primary antibody for 2 hours at 37 °C, or overnight at 4 °C with agitation. Samples require induction for efficent signal. Please refer to positive control section. |
| Notes |
|---|
|
IHC-P
Use at an assay dependent concentration. |
|
WB
1/500 - 1/1000. Predicted molecular weight: 84 kDa. Block membrane by incubating 1 hour at room temperature or overnight at 4 °C with shaking in Blocking Solution(5% BSA, 1X TBS, 0.1% Tween-20). Incubate the membrane with diluted primary antibody for 2 hours at 37 °C, or overnight at 4 °C with agitation. Samples require induction for efficent signal. Please refer to positive control section. |
Target
-
Function
Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. -
Tissue specificity
Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level). -
Sequence similarities
Belongs to the PI3K p85 subunit family.
Contains 1 Rho-GAP domain.
Contains 2 SH2 domains.
Contains 1 SH3 domain. -
Domain
The SH3 domain mediates the binding to CBLB, and to HIV-1 Nef. -
Post-translational
modificationsPolyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation.
Phosphorylated. Dephosphorylated by PTPRJ. - Information by UniProt
-
Database links
- Entrez Gene: 5295 Human
- Entrez Gene: 18708 Mouse
- Entrez Gene: 25513 Rat
- Omim: 171833 Human
- SwissProt: P27986 Human
- SwissProt: P26450 Mouse
- SwissProt: Q63787 Rat
- Unigene: 132225 Human
see all -
Alternative names
- GRB1 antibody
- p85 alpha antibody
- p85 antibody
see all
Images
-
Western blot - Anti-PI 3 Kinase p85 alpha (phospho Y607) antibody (ab182651)All lanes : Anti-PI 3 Kinase p85 alpha (phospho Y607) antibody (ab182651) at 1/500 dilution
Lane 1 : Insulin treated HeLa cell lysates
Lane 2 : HeLa cell lysates
Secondary
All lanes : HRP-conjugate secondary antibody
Predicted band size: 84 kDaBlocking solution: 5% BSA
Blocking for 1 hour at room temperature
Primary incubation overnight at 4°C
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PI 3 Kinase p85 alpha (phospho Y607) antibody (ab182651)Immunohistochemistry of human brain tissue labeling PI 3 Kinase p85 (phospho Y607) with ab182651 at 1/200.
-
Western blot - Anti-PI 3 Kinase p85 alpha (phospho Y607) antibody (ab182651)All lanes : Anti-PI 3 Kinase p85 alpha (phospho Y607) antibody (ab182651) at 1/500 dilution
Lane 1 : Rat liver extract
Lane 2 : Rat liver extract with antigen-specific peptide
Predicted band size: 84 kDa -
Western blot - Anti-PI 3 Kinase p85 alpha (phospho Y607) antibody (ab182651)All lanes : Anti-PI 3 Kinase p85 alpha (phospho Y607) antibody (ab182651) at 1/750 dilution
Lane 1 : MCF-7 cell lysate with N-Peptide
Lane 2 : MCF-7 cell lysate
Lane 3 : MCF-7 cell lysate with P-Peptide
Lane 4 : Mouse brain tissue lysate with N-Peptide
Lane 5 : Mouse brain tissue lysate
Lane 6 : Mouse brain tissue lysate with P-Peptide
Lane 7 : Rat brain tissue lysate with N-Peptide
Lane 8 : Rat brain tissue lysate
Lane 9 : Rat brain tissue lysate with P-Peptide
Lysates/proteins at 40 µg per lane.
Predicted band size: 84 kDa
Observed band size: 80 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutes
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (376)
ab182651 has been referenced in 376 publications.
- Fu J et al. MicroRNA-451a prevents cutaneous squamous cell carcinoma progression via the 3-phosphoinositide-dependent protein kinase-1-mediated PI3K/AKT signaling pathway. Exp Ther Med 21:116 (2021). PubMed: 33335579
- Chen X et al. Combination of Sodium Cantharidinate with Cisplatin Synergistically Hampers Growth of Cervical Cancer. Drug Des Devel Ther 15:171-183 (2021). PubMed: 33469269
- Li H et al. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling. Aging (Albany NY) 13:4522-4551 (2021). PubMed: 33495420
- Lv S et al. QiShenYiQi pill activates autophagy to attenuate reactive myocardial fibrosis via the PI3K/AKT/mTOR pathway. Aging (Albany NY) 13:5525-5538 (2021). PubMed: 33582656
- Wu C et al. LncRNA WT1-AS/miR-494-3p Regulates Cell Proliferation, Apoptosis, Migration and Invasion via PTEN/PI3K/AKT Signaling Pathway in Non-Small Cell Lung Cancer. Onco Targets Ther 14:891-904 (2021). PubMed: 33603394